HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Regression of pulmonary MALT lymphoma after treatment with rituximab.

Abstract
We describe a patient with extranodal (pulmonary) marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) who was refractory to treatment with cytotoxic chemotherapy. After a single four-week course of rituximab she had significant regression of pulmonary lesions and remains progression free 19 months after finishing her treatment. This case report demonstrates the potential efficacy of rituximab as a single therapeutic agent in patients with pulmonary MALT lymphoma.
AuthorsElise A Chong, Jakub Svoboda, Sindhu Cherian, Charalambos Andreadis, Lisa H Downs, Hongming Zhuang, Abass Alavi, Donald E Tsai, Stephen J Schuster
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 46 Issue 9 Pg. 1383-6 (Sep 2005) ISSN: 1042-8194 [Print] United States
PMID16109620 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
Topics
  • Adult
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Disease-Free Survival
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Lung Neoplasms (drug therapy)
  • Lymphoma, B-Cell, Marginal Zone (drug therapy)
  • Rituximab

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: